Exopolysaccharide-producing probiotic Lactobacilli reduce serum cholesterol and modify enteric microbiota in ApoE-deficient mice

J Nutr. 2014 Dec;144(12):1956-62. doi: 10.3945/jn.114.191627. Epub 2014 Oct 15.

Abstract

Background: Probiotic bacteria have been associated with a reduction in cardiovascular disease risk, a leading cause of death and disability.

Objectives: The aim of this study was to assess the impact of dietary administration of exopolysaccharide-producing probiotic Lactobacillus cultures on lipid metabolism and gut microbiota in apolipoprotein E (apoE)-deficient mice.

Methods: First, we examined lipid metabolism in response to dietary supplementation with recombinant β-glucan-producing Lactobacillus paracasei National Food Biotechnology Centre (NFBC) 338 expressing the glycosyltransferase (Gtf) gene from Pediococcus parvulus 2.6 (GTF), and naturally exopolysaccharide-producing Lactobacillus mucosae Dairy Product Culture Collection (DPC) 6426 (DPC 6426) compared with the non-β-glucan-producing isogenic control strain Lactobacillus paracasei NFBC 338 (PNZ) and placebo (15% wt:vol trehalose). Second, we examined the effects on the gut microbiota of dietary administration of DPC 6426 compared with placebo. Probiotic Lactobacillus strains at 1 × 10(9) colony-forming units/d per animal were administered to apoE(-/-) mice fed a high-fat (60% fat)/high-cholesterol (2% wt:wt) diet for 12 wk. At the end of the study, aortic plaque development and serum, liver, and fecal variables involved in lipid metabolism were analyzed, and culture-independent microbial analyses of cecal content were performed.

Results: Total cholesterol was reduced in serum (P < 0.001; ∼33-50%) and liver (P < 0.05; ∼30%) and serum triglyceride concentrations were reduced (P < 0.05; ∼15-25%) in mice supplemented with GTF or DPC 6426 compared with the PNZ or placebo group, respectively. In addition, dietary intervention with GTF led to increased amounts of fecal cholesterol excretion (P < 0.05) compared with all other groups. Compositional sequencing of the gut microbiota revealed a greater prevalence of Porphyromonadaceae (P = 0.001) and Prevotellaceae (P = 0.001) in the DPC 6426 group and lower proportions of Clostridiaceae (P < 0.05), Peptococcaceae (P < 0.001), and Staphylococcaceae (P < 0.01) compared with the placebo group.

Conclusion: Ingestion of exopolysaccharide-producing lactobacilli resulted in seemingly favorable improvements in lipid metabolism, which were associated with changes in the gut microbiota of mice.

Keywords: cholesterol; exopolysaccharide; gut microbiota; lactobacilli; lipid metabolism; probiotics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins E / genetics
  • Atherosclerosis / prevention & control
  • Cholesterol / blood*
  • Diet
  • Dietary Supplements
  • Disease Models, Animal
  • Feces / microbiology
  • Gastrointestinal Tract / microbiology
  • Gene Expression Regulation, Enzymologic
  • Glycosyltransferases / genetics
  • Glycosyltransferases / metabolism*
  • Lactobacillus / genetics
  • Lactobacillus / metabolism*
  • Lipid Metabolism*
  • Liver / metabolism
  • Mice
  • Mice, Knockout
  • Microbiota*
  • Pediococcus / enzymology
  • Probiotics / administration & dosage*
  • Triglycerides / blood
  • Vascular Cell Adhesion Molecule-1 / blood
  • beta-Glucans / blood

Substances

  • Apolipoproteins E
  • Triglycerides
  • Vascular Cell Adhesion Molecule-1
  • beta-Glucans
  • Cholesterol
  • Glycosyltransferases